Event Participants
Executives
3 Ashish Desai, Priya Gandhi, Rajiv Gandhi
Analysts
7 Ankit Kanodia, Dhruv Bajaj, Gunit Singh, Madhur Rathi, Manish Jain, Prarit Chopra, Samarth
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Standalone Revenue from Operations | +14% YoY | Growth driven by favorable product mix and operational efficiencies |
| Standalone PAT | +88% YoY | Significant improvement reflecting stronger operating performance |
| Standalone Gross Margin | 78% | Improved from 69% YoY (+900 bps), supported by favorable product mix and operational efficiencies |
| Standalone EBITDA | +95% YoY | Reflecting disciplined execution across business |
| Consolidated Revenue from Operations | -8% YoY | Decline primarily due to lower revenues from Nepal and Africa operations |
| Consolidated Debt | ₹103 crores | As of 30 June 2026, post debt reduction in Africa entity |
| Africa Soft Loan (Gates Foundation) | USD 5 million | Reduced from USD 12 million; accrued interest waived; revised loan made interest-free |
| Africa Tax-Free Status | Till 2030 | 10-year tax-free status on profits for Africa entity |
| Capacity Utilization | ~60-65% | Across entire manufacturing setup including new fill-finish and BSL3 facilities |
| Poultry Healthcare Division Revenue | +48% YoY | Supported by higher institutional business, deeper market penetration, customer engagement |
| Animal Healthcare Division | Timing-impacted | Government-led immunization programs (PPR eradication, Lumpy Skin Disease) delayed |
Geographic & Segment Commentary
Poultry Healthcare Division: Delivered 48% YoY growth driven by higher institutional business, deeper market penetration, and strengthened customer engagement. Early traction in Poultry Health Products Portfolio (feed supplements, disinfectants) launched in prior year. Management pursuing holistic disease prevention approach combining vaccines with biosecurity, farm hygiene, gut health products, and scientific advisory. Low pathogen avian influenza vaccine approved in March 2026 seeing "very good" market response contributing to growth.
Animal Healthcare Division: Impacted by timing delays in government-led immunization programs, particularly PPR eradication and Lumpy Skin Disease Control Initiative (Goat Pox vaccine). Management emphasizes this is timing-related, not demand-related. Preventive animal healthcare remains significant long-term opportunity. Focus on building balanced business across institutional, commercial, and export markets.
International Operations (Nepal & Africa): Both regions reported low revenues in Q1. Africa operations in "formative period" - new territory with geopolitical and economic challenges creating demand creation challenges. Nepal plant partially dependent on global PPR eradication program; India doesn't yet recognize regulatory changes that world recognizes. Management remains confident in long-term strategic direction focusing on registration, market development, and commercial presence. Africa entity has tax-free status till 2030.
Company-Specific & Strategic Commentary
R&D Pipeline Expansion: Submitted regulatory dossiers in animal health segment during quarter. Brucella recombinant vaccine development progressing with "significant progress" per management. Scientific innovation viewed as long-term process requiring sustained investment and regulatory discipline.
Manufacturing Infrastructure: BSL3 biosafety level 3 facility and fill-finish facility operational. Entire manufacturing setup (including new facilities) at ~60-65% utilization. Facilities are fungible between poultry and large animal vaccines. BSL3 brings different biosafety capabilities for specialized biological products under development - specific products and market potential not disclosed.
Pet Care Division: Emerging division, currently part of Animal Health business (not reported separately). Portfolio includes antibiotics, anti-parasites, grooming products selling under Hester brand. Management committed to "Make in India" approach - producing vaccines domestically rather than importing. Vaccines for pet segment premature; regulatory timelines stringent. Distribution leverages existing Animal Health network and Hester's veterinary credibility.
Holistic Poultry Solutions Strategy: Positioning vaccination not as standalone intervention but combined with biosecurity, hygiene, and health products. Same distribution network sells both vaccines and health products. Philosophy focuses on integrated disease prevention to improve farm productivity.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Africa Operations | No guidance provided | Management refuses directional guidance; "formative period" with geopolitical volatility; will "take it as it comes" |
| Capacity Utilization | No specific target | Working towards "optimum utility" of manufacturing facility; no percentage guidance given |
| Pet Care Vaccines | No timeline | Premature to comment; regulatory timelines stringent; committed to domestic production |
| Brucella Recombinant Vaccine | No launch timeline | Significant progress; will announce when appropriate for public domain |
| Overall FY27 Priorities | Qualitative only | Strengthen biological portfolio, expand domestic/export market penetration, advance R&D pipeline, improve manufacturing utilization, maintain operational excellence |
Risks & Constraints
| Risk | Context |
|---|---|
| Government Tender Timing Volatility | Animal Healthcare division dependent on government immunization programs (PPR, Lumpy Skin Disease); delays are administrative/policy-driven, not demand-driven; management acknowledges timing risk but emphasizes long-term steady business over multi-year periods |
| Africa Geopolitical & Operational Risk | "Formative period" in virgin continent with struggling economies and political instability; demand creation challenging; willingness exists but ability constrained by geopolitical factors; no visibility on scaling trajectory |
| Regulatory Pathway Uncertainty (Avian Influenza) | Government yet to determine regulatory pathway for HPAI vaccines (import vs domestic manufacture); premature to assess opportunity; dependent on policy, regulatory framework, and disease situation |
| New Product Regulatory Timelines | Pet vaccines and pipeline products face stringent regulatory demands; timelines uncertain; management committed to domestic development over import-and-sell model |
| Cash Conversion / Receivables | Analyst raised concern about weak cash conversion; management acknowledges receivables "a little higher" due to seasonal issues but states not a concern, manageable, no red flag |
| Nepal Market Dependency | Nepal plant utilization partly tied to global PPR eradication program; India's regulatory non-recognition of global changes creates dependency on export markets for this facility |
Q&A Highlights
Avian Influenza Vaccine Opportunity
- Question: Recent Ministry meeting on HPAI and vaccine import for testing - how does this create opportunities? (Ankit Kanodia)
- Answer: Premature to comment; government must first determine regulatory pathway (import vs domestic manufacture); development highly dependent on policy, regulatory framework, disease situation; monitoring but cannot speculate (Priya Gandhi)
Farmer Compensation for Culling
- Question: News about compensation not paid to farmers for H5N1 culling - impact on industry? (Ankit Kanodia)
- Answer: Not within company's purview (insurance/government/farmers); no impact on industry at this point; discussions not raised in manufacturers' association meetings (Rajiv Gandhi)
Poultry Division Growth Drivers
- Question: Poultry growing fast vs historical track record - cyclical or structural? Breakup value/volume? (Dhruv Bajaj)
- Answer: Market dynamics force business between divisions; government vaccine tender delays hurt Animal Health while Poultry captured opportunities; not worried about divisional imbalance; both divisions targeted to grow together (Rajiv Gandhi). Growth from market share gains, not price increases; prices marginally up; aggressive market penetration, scientific engagement, health products expansion (Priya Gandhi, Rajiv Gandhi)
Africa Operations Trajectory
- Question: Africa scaling challenges - gestation period or tender troubles? Green shoots? (Dhruv Bajaj)
- Answer: Combined factors - new territory, virgin continent, struggling economies, political instability, demand creation; "formative period" not gestation; positive results emerging; will take off in time; no directional guidance (Rajiv Gandhi)
BSL3 & Fill-Finish Facility Utilization
- Question: Current utilization of BSL3/fill-finish capacity? Ramp-up plan? (Dhruv Bajaj)
- Answer: Difficult to give percentage; BSL3 is regulated requirement for future; proud of facility; working towards optimum utility for veterinary product pipeline; no capacity utilization number (Priya Gandhi). Overall plant utilization ~60-65% including new facilities (Rajiv Gandhi)
Low Pathogen Avian Influenza Vaccine
- Question: Market feedback on vaccine approved March 2026? (Manish Jain)
- Answer: Market response "very good"; selling the vaccine; contributed to poultry division growth jumps (Rajiv Gandhi)
Pet Care Vaccines & Make in India
- Question: When to launch pet vaccines? (Manish Jain)
- Answer: Premature; regulatory timelines stringent; working towards it; committed to "Make in India, produce in India, sell from India" - not dependent on imports; want to sell abroad (Priya Gandhi, Rajiv Gandhi)
Consolidated Debt & Africa Tax Status
- Question: Consolidated debt post reduction? Africa tax-free status year? (Manish Jain)
- Answer: Consolidated debt ₹103 crores as of 30 June 2026 (Ashish Desai). Africa tax-free status till 2030 (Ashish Desai)
Capacity Utilization Details
- Question: Rough capacity and utilization to understand headroom? (Ankit Kanodia)
- Answer: ~60-65% utilization; subjective due to multiple products (1000-dose poultry, 25-dose large animal, pet vaccines, various dose sizes); average approximation (Rajiv Gandhi)
Fill-Finish & BSL3 Capabilities
- Question: Do new facilities bring new capabilities/products? Market potential? (Gunit Singh)
- Answer: Fill-finish different from existing; BSL3 different biosafety level; pipeline products not appropriate to disclose; will announce launches subsequently (Priya Gandhi)
Nepal & Africa Demand Environment
- Question: Demand environment and profitability timeline? (Gunit Singh)
- Answer: Africa opportunities extremely positive in healthcare; Nepal dependent on global PPR eradication; India doesn't recognize global regulatory changes; will utilize overseas plants for that demand; opportunities huge (Priya Gandhi)
Pet Care Division Scale & Model
- Question: Current revenues, profitability, B2C model, distribution size? (Gunit Singh)
- Answer: Emerging division, part of Animal Health (not reported separately); products: antibiotics, anti-parasites, grooming; doing well; investments ongoing; distribution part of Animal Health network nationally; Hester's veterinary credibility helps (Priya Gandhi)
Brucella Recombinant Vaccine & Poultry Exports
- Question: Update on Brucella recombinant vaccine? Poultry vaccines in Nepal/Africa? (Samarth)
- Answer: Brucella development on proper timeline with significant progress; will disclose when appropriate (Priya Gandhi). Poultry vaccines already selling in Africa and Nepal; manufactured across all three facilities; poultry market huge in all countries (Priya Gandhi, Rajiv Gandhi). Nepal market size disputed - management doesn't believe it's ₹100 crore (Rajiv Gandhi)
Cross-Selling Feed Supplements
- Question: Penetration of feed supplements through poultry network? Revenue improvement direction? (Madhur Rathi)
- Answer: No separate network - same distribution sells vaccines and health products; philosophy is holistic disease prevention combining vaccination with biosecurity, hygiene, health products; no bifurcation/segregation (Priya Gandhi, Rajiv Gandhi)
Animal Vaccine Geographical Expansion
- Question: Strategy to increase geographical presence for outbreak-driven demand? (Madhur Rathi)
- Answer: Not outbreak-driven; preventive solution with planned schedules like human health; Government serious on disease control; execution delays administrative/policy; diseases and vaccines planned; not rushing to outbreaks (Priya Gandhi)
Key Takeaway
Hester Biosciences delivered strong standalone Q1 FY27 results with revenue +14% YoY, PAT +88%, gross margins expanding 900 bps to 78%, and EBITDA +95%, driven by Poultry Healthcare's 48% growth from market share gains, holistic disease prevention strategy (vaccines + feed supplements + biosecurity), and favorable mix. Consolidated revenue declined 8% due to Nepal/Africa weakness, though Africa's Gates Foundation loan was restructured (USD 12M→5M, interest-free) and entity retains tax-free status till 2030. Manufacturing utilization at 60-65% including new BSL3/fill-finish facilities provides significant headroom. Strategic focus remains on R&D pipeline (Brucella recombinant progressing, regulatory dossiers submitted), pet care expansion (domestic production commitment), and balancing Animal Health's government tender volatility with commercial/export growth. Management refuses quantitative guidance on Africa scaling, capacity ramp-up, or product timelines, emphasizing long-term "formative period" investments. Key risks: government tender timing, Africa geopolitical volatility, regulatory uncertainty on HPAI vaccines, and receivables seasonality.